Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
During thoracic aortic surgery, hypothermic cardiac arrest causes aortic ischemia and
reperfusion (IR) periods, respectively. Aortic ischemia results in an ischemic insult to the
lower extremities and successive reperfusion results in injury to remote organs, including
kidneys. So, there has been considerable interest in the development of therapeutic
strategies aimed at attenuating IR injury. One such group of agents that are attracting
interest due to their potential protective effects on vascular endothelium is the
erythropoietin.
However, the effect of erythropoietin on renal injury induced by aortic IR in humane has not
been fully clarified. Therefore, the purpose of this study is to determine whether the
prophylactic administration of erythropoietin reduce the incidence of acute kidney injury
(AKI) in patients undergoing thoracic aorta surgery with hypothermic cardiac arrest. The
investigators administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min
before the commencement of ischemia. The differences between the control and study groups are
observed by clinical indicators such as serum creatinine, TNF-α, NGAL.